CXCL13 and neoplasm: Similarly, a recent report of human advanced gastric cancer and anti-PD-1 plus chemotherapy suggested that the addition of Pembrolizumab (αPD-1) to 5-FU/oxaliplatin chemotherapy enhances T cell antitumor immune remodeling, especially CXCL13+ CD8+ T cells which covaries with multiple tumor-reactive phenotypes [436].